Concerns on Bebtelovimab (LY‐CoV1404) used to neutralize Omicron subvariants.

The pseudovirus neutralization assays showed that XBB.1 and BQ.1.1 could not be blocked by Bebtelovimab, while BA.2.3.20 was approximately seven fold resistant to Bebtelovimab (Figure 1B). Bebtelovimab (LY-CoV1404) is a monoclonal antibody showing remarkable neutralizing capacity against all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) as of June 2022, including the Omicron variant and its subvariants (BA.1, BA.2, BA.4, and BA.5).[[1]] However, SARS-CoV-2 continues to acquire mutations in the spike that impact antibody recognition and neutralization.[[3]] It is important to evaluate the efficiency of Bebtelovimab against new SARS-CoV-2 variants and provide a reference for the application of Bebtelovimab. In summary, the neutralizing antibody Bebtelovimab was escaped by more and more SARS-CoV-2 variants, including new-emerging variants BQ.1.1, XBB.1, and potential future variants. [Extracted from the article]